Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions

Low molecular weight heparins (LMWH) and anti-Xa direct oral anti-coagulants (DOACs) are recommended for the long-term treatment of cancer-associated thrombosis (CAT) based on well-documented randomised controlled trials. Anti-Xa DOACs are viewed as a first choice for the treatment of patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Grange, Claire, Rioufol, Catherine, Souquet, Pierre-Jean, Assaad, Souad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582124/
https://www.ncbi.nlm.nih.gov/pubmed/37824026
http://dx.doi.org/10.1007/s40262-023-01298-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582124/
https://www.ncbi.nlm.nih.gov/pubmed/37824026
http://dx.doi.org/10.1007/s40262-023-01298-4

Ejemplares similares